DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure

Information source: The Alfred
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heart Failure; Chronic Obstructive Airway Disease

Intervention: Carvedilol (Drug); Metoprolol (Drug)

Phase: Phase 4

Status: Withdrawn

Sponsored by: The Alfred

Official(s) and/or principal investigator(s):
Henry Krum, Professor, Principal Investigator, Affiliation: Monash University / Alfred Hospital


This study looks at the effect of two drugs (carvedilol and metoprolol) which are used for patients with CHF (chronic heart failure). These agents are beta-blockers and, although effective in heart failure, may cause increases in airways tone and thus limit air getting into the lower parts of the lungs. Carvedilol is more active at blocking the receptor that opens up the airways and therefore theoretically may be more likely to reduce airways tone than metoprolol, although this has never been studied in patients with heart failure, and that is the purpose of the present study. We are looking to enrol 45 patients with heart failure and mild obstruction to the flow of air in their lungs. Patients will be randomised to either carvedilol or metoprolol (standard doses). Following a minimum of 2 weeks of therapy of study medication the patient will undergo a study day involving an assessment of their lung function, an assessment of their heart failure, a "living with heart failure" questionnaire, blood tests and blood pressure and heart rate readings. Patients will then be crossed over to the alternate medication. Following 2 weeks on the target dose the patient will undergo their second study day which will be the same as the first. The results obtained from each study day will be compared.

Clinical Details

Official title: The CAMERA Study: CArvedilol MEtoprolol Respiratory Assessment Investigator Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Respiratory function

NYHA class with the use of the 7 point scale (Packer).

Minnesota "living with Heart Failure" questionnaire.


BP and HR

plasma N-terminal pro-BNP


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- males and females over 18 years of age

- Documented CHF (NYHA class II-IV symptoms)

- Airflow obstruction defined as patients with symptomatic obstructive respiratory

disease as manifest by any of the following Symptoms of wheeze, primarily attributed to airflow obstruction Requirement for intermittent or regular bronchodilator therapy FEV1 less than 70% predicted pre-salbutamol

- Confirmed written informed consent.

- Clinically indicated to receive β-blockade.

- No evidence of heart block on ECG.

- Patients will be in one of the following categories:

Currently on carvedilol Currently on Toprol-XL or Metoprolol tartrate Currently on bisoprolol Clinically indicated to receive β adrenoceptor blockade but not currently prescribed a β-blocker. Exclusion Criteria:

- Women lactating, pregnant or of childbearing potential not using a reliable

contraceptive method.

- Patients who had received an investigational new drug within the last 4 weeks.

- Patients with a history of a psychological illness or condition such as to interfere

with the patient's ability to understand the requirements of the study.

- Laboratory parameters:

Creatinine >0. 30 mmol/l Liver function tests 3x ULN

- Recent (<12 months) myocarditis

Locations and Contacts

Alfred Hospital, Melbourne, Victoria 3004, Australia
Additional Information

Starting date: June 2005
Last updated: June 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017